Randomized Phase II Trial Of Hypofractionated Dose-Escalated Photon IMRT Or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant And Adjuvant Temozolomide In Patients With Newly Diagnosed Glioblastoma (NRG-BN001)(CIRB)
The standard of care for glioblastoma is the anticancer drug temozolomide plus radiation therapy. In this study, researchers want to see if using a higher dose of radiation therapy is more effective than standard-dose radiotherapy for newly diagnosed glioblastoma, and see if this new treatment causes more side effects.
Patients in this study will be randomly assigned to receive standard-dose radiation with intensity-modulated radiation therapy (IMRT), or higher-dose radiation therapy with IMRT or proton beam therapy. All patients in the study will also receive temozolomide, which is taken orally (by mouth) once a day.
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have newly diagnosed glioblastoma.
- Patients may not have previously received chemotherapy (including temozolomide) for glioblastoma or radiation therapy to the head and neck.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Mariza Daras at 212-610-0239.